FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Marketing

False, Misleading Claims in Xatmep Professional E-Mail: OPDP

CDERs Office of Prescription Drug Promotion notifies Azurity about violations in a healthcare professional e-mail for the companys Xatmep.

Biologics

Panel Backs Pfizer Covid-19 Vaccine

FDAs Vaccines and Related Biological Products Advisory Committee votes to recommend an Emergency Use Authorization for Pfizer-BioNTechs Covid-19 vacci...

Human Drugs

X4 Pharma Gets Rare Pediatric Disease Status

FDA grants X4 Pharmaceuticals a rare pediatric disease designation for mavorixafor for treating WHIM (Warts, Hypogammaglobulinemia, Infections, and My...

Human Drugs

FDA Accepts Atox Bio NDA Filing for Reltecimod

FDA accepts for filing an Atox Bio NDA for reltecimod to treat patients with necrotizing soft tissue infections.

Medical Devices

Researchers Find No Excess Deaths in Paclitaxel-Coated Devices

Swedish researchers say they found no significant increase in the risk of death in patients who received paclitaxel-coated devices to treat peripheral...

Human Drugs

Stakeholders Comment on Breast Cancer Draft Guidance

Stakeholders support an FDA recommendation to include premenopausal women in breast cancer drug development programs.

Biologics

FDA to Warn About Severe Reactions with Covid Vaccine: Marks

CBER director Peter Marks says FDA plans to warn patients whove had previous severe reactions after being vaccinated about such risks with Pfizer-BioN...

Biologics

Pfizer BLA Accepted for Pneumococcal Conjugate Vaccine

FDA accepts for priority review a Pfizer BLA for its 20-valent pneumococcal conjugate vaccine and its us for preventing invasive disease and pneumonia...

Medical Devices

SoniVie Breakthrough Status for Hypertension Device

FDA grants SoniVie a breakthrough device designation for the Tivus System for renal artery denervation and its use in treating resistant hypertension.

FDA General

HHS Good Guidance Rules Could Ossify FDA: Analysis

Attorney T. Daniel Logan analyzes the impact on FDA of HHS regulations on good guidance practices.